2-氟联苯-4-羧酸 | 365-12-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氟联苯-4-羧酸
• 中文别名: 2'-氟联苯-4-羧酸；2'-氟二苯-4-甲酸
• 英文名称: 2'-Fluor-biphenyl-4-carbonsaeure
• 英文别名: 4-(2-fluorophenyl)benzoic acid；2'-Fluorobiphenyl-4-carboxylic acid
• CAS: 365-12-8
• 化学式: C₁₃H₉FO₂
• 分子量: 216.212
• InChiKey: SLKZDWAZOKIEEU-UHFFFAOYSA-N

物化性质

• 熔点：
  230-232℃
• 沸点：
  363.9±25.0 °C(Predicted)
• 密度：
  1.261±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2916399090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

SDS

Name:	2 -Fluoro[1 1 -biphenyl]-4-carboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	365-12-8

Section 1 - Chemical Product MSDS Name:2 -Fluoro[1 1 -biphenyl]-4-carboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
365-12-8	2'-Fluoro[1,1'-biphenyl]-4-carboxylic	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 365-12-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 234 - 236 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C13H9FO2
Molecular Weight: 216.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 365-12-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2'-Fluoro[1,1'-biphenyl]-4-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 365-12-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 365-12-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 365-12-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氟联苯-4-羧酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N'-羰基二咪唑 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  联苯咪唑衍生物作为有效的抗真菌剂的发现：设计，合成和构效关系研究

  摘要：

  真菌感染由于其高发病率和高死亡率而已成为严重的医学问题。我们描述了一系列新型联苯咪唑衍生物的发现和构效关系研究（SAR），这些衍生物对白色念珠菌和新隐球菌具有优异的抗真菌活性。最有前途的化合物12f – g和19a – b表现出出色的活性，最小抑菌浓度（MIC）值在0.03125–2μg/ mL的范围内。初步机理研究表明，化合物12g的有效抗真菌活性源于对白色念珠菌中CYP51的抑制作用。。此外，化合物12g和19b对多种人细胞色素P450同工型表现出低抑制特性。在这项研究中建立的SAR和绑定模式将有助于进一步优化潜在客户。

  DOI：

  10.1016/j.bmc.2016.11.051
• 作为产物：
  描述：

  1-[4-(2-氟苯基)苯基]乙酮 在 sodium hypobromide 作用下， 以 1,4-二氧六环 为溶剂， 生成 2-氟联苯-4-羧酸
  参考文献：
  名称：

  一些取代的联苯-4-羧酸，4-联苯基乙酸和4-氨基联苯的合成

  摘要：

  描述了一系列取代的联苯-4-羧酸和4-氨基联苯的合成。包括母体联苯-4-羧酸，4-联苯基乙酸和三种取代的4-联苯基乙酸的制剂。

  DOI：

  10.1039/j39660000840

文献信息

• [EN] HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] AGENTS RECEPTEURS DE L'HISTAMINE H3, PREPARATION ET UTILISATIONS THERAPEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2005097740A1

  公开（公告）日：2005-10-20

  The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases

  本发明公开了具有组合物(I)或其药学上可接受的盐的新颖化合物，其具有组胺H3受体拮抗剂或逆激动剂活性，以及制备这种化合物的方法。在另一实施例中，本发明公开了包含组合物(I)的药物组合物，以及使用它们治疗肥胖、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。
• HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
  申请人：Beavers Lisa Selsam

  公开号：US20100048580A1

  公开（公告）日：2010-02-25

  The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases

  本发明公开了化合物(I)的新颖化合物或其药学上可接受的盐，其具有组胺H3受体拮抗剂或逆激动剂活性，以及制备这种化合物的方法。在另一实施方案中，本发明公开了包含化合物(I)的药物组合物，以及使用它们治疗肥胖、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。
• Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives
  作者：Liyu Zhao、Wenbo Yin、Yin Sun、Nannan Sun、Linfeng Tian、Yang Zheng、Chu Zhang、Shizhen Zhao、Xin Su、Dongmei Zhao、Maosheng Cheng

  DOI：10.1016/j.ejmech.2021.113715

  日期：2021.11

  l-amino alcohol derivatives exhibited high antifungal activity, but the metabolic stability of human liver microsomes in vitro was poor, and the half-life of optimal compound 5 was less than 5 min. To improve the metabolic properties of the compounds, the scaffold hopping strategy was adopted and a series of antifungal compounds with a dihydrooxazole scaffold was designed and synthesized. Compounds

  l-氨基醇衍生物具有较高的抗真菌活性，但人肝微粒体体外代谢稳定性较差，最佳化合物5的半衰期小于5 min。为改善化合物的代谢特性，采用支架跳跃策略，设计合成了一系列具有二氢恶唑支架的抗真菌化合物。二氢恶唑环上被4-苯基取代的化合物A33-A38对白色念珠菌、热带念珠菌和克氏念珠菌表现出优异的抗真菌活性，MIC值在0.03~0.25  μ之间。克/毫升。此外，化合物A33和A34在体外人肝微粒体中的代谢稳定性显着提高，半衰期分别大于145 min和59.1 min。此外，SD大鼠的药代动力学研究表明，A33具有良好的药代动力学特性，生物利用度为77.69%，半衰期（静脉给药）为9.35 h，表明A33值得进一步研究。
• Design, synthesis, and structure-activity relationship studies of l-amino alcohol derivatives as broad-spectrum antifungal agents
  作者：Liyu Zhao、Linfeng Tian、Nannan Sun、Yin Sun、Yixuan Chen、Xinran Wang、Shizhen Zhao、Xin Su、Dongmei Zhao、Maosheng Cheng

  DOI：10.1016/j.ejmech.2019.05.047

  日期：2019.9

  To discover broad spectrum antifungal agents, two strategies were applied, and a novel class of l-amino alcohol derivatives were designed and synthesized. 3-F substituted compounds 14i, 14n, 14s and 14v exhibited excellent antifungal activities with broad antifungal spectra against C. albicans and C. tropicalis, with MIC values in the range of 0.03–0.06 μg/mL, and against A. fumigatus and C. neoformans

  为了发现广谱抗真菌剂，应用了两种策略，并且设计并合成了一类新型的1-氨基醇衍生物。3-F取代的化合物14i，14n，14s和14v表现出优异的抗真菌活性，对白念珠菌和热带念珠菌具有宽泛的抗真菌谱，MIC值在0.03-0.06μg/ mL范围内，对烟曲霉和C新甲虫，MIC值在1-2μg/ mL的范围内。值得注意的是，化合物14i，14n，14s和14v还显示出对从艾滋病患者中分离出的耐氟康唑耐药菌株17＃和CaR的中等活性。而且，仅S构型的化合物显示出抗真菌活性。初步的机理研究表明，化合物14v的有效抗真菌活性源于对白色念珠菌CYP51的抑制。化合物14n和14v对哺乳动物A549细胞几乎无毒，它们在人血浆中的稳定性非常好。
• Combating fluconazole-resistant fungi with novel β-azole-phenylacetone derivatives
  作者：Liyu Zhao、Nannan Sun、Linfeng Tian、Yin Sun、Yixuan Chen、Xinran Wang、Shizhen Zhao、Xin Su、Dongmei Zhao、Maosheng Cheng

  DOI：10.1016/j.ejmech.2019.111689

  日期：2019.12

  excellent antifungal activities against five pathogenic strains with MIC values in the range of 0.03-1 μg/mL. Compounds with R1 = 3-F substituted and 15o and 15ae exhibited moderate antifungal activities against fluconazole-resistant strains 17# and CaR with MIC values in the range of 1-8 μg/mL. Compounds with R1 = H or 2-F (such as 15a, 15o, 15p) displayed moderate to good antifungal activity against

  设计并合成了一系列具有新颖结构的β-唑-苯丙酮衍生物，以抵抗易感真菌感染和耐药真菌感染的增加。评估了合成化合物对五种敏感菌株和五种耐氟康唑的菌株的抗真菌活性。抗真菌活性测试表明，大多数化合物对5种病原菌株均表现出优异的抗真菌活性，其MIC值在0.03-1μg/ mL的范围内。R1 = 3-F取代且15o和15ae的化合物对MIC范围为1-8μg/ mL的耐氟康唑耐药菌株17＃和CaR表现出中等的抗真菌活性。R1 = H或2-F（例如15a，15o，15p）的化合物对耐氟康唑的菌株632具有中等至良好的抗真菌活性，901和904的MIC值在0.125-4μg/ mL的范围内。值得注意的是，15o和15ae对五种敏感菌株和五种对氟康唑耐药的菌株均表现出抗真菌活性。初步的机理研究表明，化合物15ae的有效抗真菌活性源于对白色念珠菌CYP51的抑制作用。化合物15o，15z和15ae对哺乳动物A549细胞几乎无毒。